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Summary Nocardiosis is a cause of significant morbidity and mortality in the immunocompro-
mised host, and is an infrequent complication of tumor necrosis factor alpha (TNF-a) blockers in
chronic inflammatory diseases. Nocardiosis occurs at a rate of 3.55 and 0.88 per 100 000 patients
treated with infliximab or etanercept, respectively. Disseminated nocardiosis remains an uncom-
mon complication of these agents. Here, we present a fatal case of disseminated systemic
nocardiosis in a patient with psoriasis following sequential therapy with alefacept and then
infliximab therapy. The patient developed disseminated disease involving the brain, lymph nodes,
and adrenal glands. The diagnosis was made by blood culture and aspiration of the adrenal gland
abscess, which revealed Gram-positive bacilli and later grew Nocardia farcinica. The organism
was identified by DNA sequencing, and was susceptible to moxifloxacin, gatifloxacin, ciproflox-
acin, amoxicillin—clavulanic acid, linezolid, sulfamethoxazole, and amikacin. It was resistant to
clarithromycin, ceftriaxone, and tobramycin and was intermediately susceptible to imipenem.
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Nocaxdia infection is not rare, as has generally been
assumed, and the associated mortality rate is high. Nocardia
spp can be isolated from plants and soil in most regions of the
world. The infection ranges from a self-limiting, sub-clinical* Corresponding author. Tel.: +966 3 877 3524; fax: +966 3 877 3790.
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Nocardia may cause infection in either normal or immuno-
compromised hosts. The infection is usually acquired through
the skin or the respiratory tract. The most common presen-
tation is pulmonary infection, which may be followed by
dissemination to multiple sites.2 Nocardia spp have a ten-
dency to disseminate hematogenously from the primary site
of infection to the brain, kidneys, joints, bones, and eyes.3
Dissemination of nocardiosis is associated with immuno-
compromised states, including those in diabetes mellitus,Published by Elsevier Ltd. All rights reserved.
Figure 1 A computerized axial tomography scan of the abdo-
men showing a 4.6  2.5 cm left adrenal mass and a 2.2  1.2 cm
right adrenal mass.
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corticosteroid therapy, HIV infection, organ transplant,
and the use of tumor necrosis factor inhibitors. Nocardiosis
is an infrequent complication of tumor necrosis factor alpha
(TNF-a) blockers in chronic inflammatory diseases. A total
of eight cases of nocardiosis were identified among approxi-
mately 300 000 patients treated with anti-TNF agents with a
rate of 3.55 and 0.88 per 100 000 patients treated with
infliximab or etanercept, respectively.4,5 Additionally,
cutaneous nocardiosis has been reported following inflix-
imab therapy6,7 and disseminated disease following etaner-
cept therapy.8 However, disseminated nocardiosis remains
an uncommon complication of these agents. Here, we
present a case of disseminated systemic nocardiosis in a
patient with psoriasis and sequential therapy with alefa-
cept and infliximab.
Case report
Thepatientwasa 66-year-oldwomanwhohadhadpsoriasis for
8 years and had diabetes mellitus type 2 and essential hyper-
tension. The psoriasis was quite refractory to topical treat-
ment, including ultraviolet light therapy. One year before
presentation, the psoriasis became extensive and covered
60% of her body surface area. Six months before presentation,
she was treated with alefacept, 15 mg intramuscularly weekly
for 12 weeks, with no improvement. Two months before pre-
sentation, she was given 100 mg infliximab weekly for two
weeks with marked improvement of the psoriasis. On the day
of admission to hospital, she presented with a fever reaching
39 8C (associatedwith rigors and profuse sweating). Therewas
no weight loss. She had left upper quadrant abdominal pain
thathad startedaweekbefore admission.Therewasnohistory
of recent travel or history of raw milk ingestion. The patient
had no known epidemiological risk factors for nocardiosis such
as gardening.
On examination, her temperature was 38.8 8C and there
was no peripheral lymphadenopathy. The skin showed slight
hyperpigmentation and a few small psoriatic lesions. Cardi-
ovascular and lung examinations were normal. The abdomen
was soft with slight non-rebound left upper quadrant tender-
ness and normal bowel sounds. There was no synovitis.
Laboratory investigations showed leukocytosis of
13.7  109/l primarily due to neutrophilia. Hemoglobin
was 12.8 g/dl and platelets were 263  109/l. C-reactive
protein was 14 mg/dl and the erythrocyte sedimentation
rate was 104 mm/h. Lactate dehydrogenase was 838 mg/dl
(normal range 321—597). Alanine aminotransferase, aspar-
tate aminotransferase, and alkaline phosphatase were
normal. Serology for Brucella and HIV 1 and 2 were nega-
tive. A skin test with purified protein derivative (PPD)
showed no induration. One out of five blood cultures
was initially reported to grow a diphtheroid species. Uri-
nalysis and culture were negative. CD4+ lymphocytes were
0.14  109/l (normal range 0.41—1.59  109/l) compared
to CD4+ counts of 0.49—0.70  109/l before and during
alefacept therapy.
A chest radiograph was normal, but computed tomography
(CT) of the abdomen showed a 4.6  2.5 cm left adrenal mass
and a 2.2  1.2 cm right adrenal mass (Figure 1). There were
multiple retroperitoneal and mesenteric lymphadenopathies
with a maximal diameter of 1.8 cm. There was partial leftrenal vein thrombosis and a wedge-shaped splenic lesion that
most likely represented an infarction.
The initial impression was infection in an immunocompro-
mised patient; however the first abdominal imaging
appeared to favor a neoplastic process. While awaiting hor-
monal studies to exclude an adrenal cortical tumor or pheo-
chromocytoma, fever persisted. After one week, naproxen
was started and the fever resolved within 24 hours, and she
temporarily felt much better. Later, the patient had a
decrease in the level of consciousness that progressed to
deep coma over a few days. CT of the head showed multiple
ring enhancing lesions scattered throughout the brain, with
slight surrounding edema (Figure 2). A repeat CT scan of the
abdomen, 16 days after the initial study, showed enlarge-
ment of both adrenal masses to 6.4 cm on the left associated
with a small amount of fluid, and 4.7 cm on the right
(Figure 3).
Magnetic resonance imaging of the brain showed numer-
ous round peripherally enhancing lesions involving superficial
and deep brain matter and white matter (Figure 4). The
lesions were surrounded by mild vasogenic edema and
demonstrated intense restricted diffusion. Several lesions
also demonstrated evidence of hemorrhage. Post-contrast
imaging demonstrated an enhancement pattern and multi-
focal areas of leptomeningeal enhancement.
Aspiration and biopsy of the left adrenal lesion yielded
8 ml of pus. Gram stain showed many pus cells and Gram-
positive bacilli. These were initially identified as diphtheroid
species, but later confirmed by modified acid-fast stain and
cultures to be Nocardia species. Mycobacterial smears and
cultures were negative. Biopsy revealed necrotic tissue and
flow cytometry showed cellular debris.
Vancomycin and ampicillin were started initially, and later
ampicillin was stopped and meropenem and voriconazole
were given. Once Nocardia spp was suspected, the patient
was treated with trimethoprim—sulfamethoxazole (TMP—
Figure 4 Magnetic resonance imaging of the brain showing
numerous round peripherally enhancing lesions involving super-
ficial and deep white matter.
Figure 2 Computed axial tomography of the brain showing
multiple ring enhancing lesions scattered throughout the brain
and slight surrounding edema.
Brucellosis presenting as myelofibrosis e155SMX) and linezolid. Although she partially improved, she
never regained full consciousness up to the time of her death.
Two and a half months after admission, the patient developed
seizure and cardiopulmonary arrest and died. A CT of the
brain shortly before death showed no significant change in
the appearance of the brain lesions.
The final culture and susceptibility results were avail-
able one week after the patient’s death and showed Nocar-
dia farcinica. The organism was identified by DNA
sequencing at the Department of Laboratory Medicine
and Pathology, Mayo Clinic, Rochester, USA. The organism
was susceptible to moxifloxacin (0.25 mg/ml), gatifloxacinFigure 3 A repeat computed axial tomography of the abdo-
men, 16 days after the initial study, showing enlargement of both
adrenal masses to 6.4 cm on the left and 4.7 cm on the right.(0.25 mg/ml), ciprofloxacin (0.5 mg/ml), amoxicillin—cla-
vulanic acid (8/4 mg/ml), linezolid (2 mg/ml), sulfamethox-
azole (4 mg/ml), and amikacin (2 mg/ml). The organism
was resistant to clarithromycin (32 mg/ml), ceftriaxone
(64 mg/ml), and tobramycin (16 mg/ml) and was interme-
diately susceptible to imipenem (8 mg/ml).
Discussion
This patient had a severe cellular immune defect secondary
to exposure to alefacept and infliximab in succession. Her
CD4+ lymphocytes were low at 0.14  109/l. She suffered
from a fatal case of systemic nocardiasis, involving the
central nervous system.
Alefacept is a recombinant, soluble leukocyte function-
associated antigen-3-immunoglobulin fusion protein that
binds to the T cell rosette receptor. Alefacept treatment
results in decreases in circulating CD4+ CD45RO+ and CD8+
CD45RO+ lymphocytes. It is used for the treatment of mod-
erate to severe plaque psoriasis in adults who are candidates
for systemic therapy. An alefacept-induced decline in circu-
lating T lymphocytes may increase the risk of infection. In the
current patient, the CD4+ lymphocyte count declined during
alefacept therapy, from 0.70 to 0.49  109/l. The manufac-
turer recommends stopping alefacept when the CD4+ lym-
phocyte count falls below 0.25  109/l. Alefacept appears to
be a safe medication.9 A patient treated with alefacept was
reported to have developed Mycobacterium avium complex
bursitis, when the CD4+ cell count was 0.298  109/l at the
time of diagnosis.10
Infliximab is a chimeric anti-TNF-a monoclonal antibody.
It binds soluble TNF-a and TNF-a receptors on macrophages
e156 J.A. Al-Tawfiq, A.A. Al-Khattiand T cells, and results in apoptosis of macrophages and T
cells. It is very effective in the treatment of resistant psor-
iasis.11 Increased susceptibility to opportunistic infections is
a recognized side effect of infliximab therapy.12 Dissemi-
nated and cutaneous nocardiasis have been reported follow-
ing anti-TNF therapy.4—7,13 A case of pulmonary nocardiosis
has also been described in a patient receiving adalimumab
therapy for refractory rheumatoid arthritis14 and a dissemi-
nated disease following etanercept therapy.8 However, dis-
seminated nocardiosis remains an uncommon complication of
these agents.
It is possible that exposure to alefacept, and then inflix-
imab, increased immunosuppression and susceptibility to
infection. However, CD4+ cells were above the recommended
level at which alefacept should be discontinued. At the time
of presentation with systemic Nocardia infection, the CD4+
cell count was very low at 0.14  109/l. The patient had
diabetes mellitus, which might have contributed to the
immune deficiency.
Nocardia species are aerobic Gram-positive bacteria that
are ubiquitous in the environment. Infection usually occurs
through inhalation or direct cutaneous inoculation of the
organism. Systemic nocardiasis is most frequently seen in
immunocompromised hosts. It has a high mortality, espe-
cially when the central nervous system is involved. Delay in
diagnosis has been reported and may contribute to a worse
prognosis. This case highlights the risk of these potent
medications. It also highlights the difficulty in making a
timely diagnosis of rare infections in immunocompromised
patients.
N. farcinica appears to be more virulent than the other
Nocardia spp and tends to result in disseminated disease.15
The distribution of Nocardia spp is different based on the
geographic location. N. farcinica accounts for 27% of spe-
cies in Japan and 44% in Belgium.16 Nocardia spp exhibit
different in vitro susceptibility patterns, therefore it is
important to obtain precise speciation and susceptibility
testing of clinical isolates.17,18 Two N. farcinica strains
were found to be resistant to antimicrobial agents, but
were susceptible to ceftriaxone and cefotaxime.19 In addi-
tion, TMP—SMX resistance has also been described in one
patient.20 Of all reported cases, a mortality rate of 35%
occurred in patients with N. farcinica. However, cerebral
nocardiosis has been associated with mortality rates of 55%
and 20% in immunocompromised and immunocompetent
patients, respectively, and may be as high as 66% in those
with multiple abscesses.21 An increase in mortality may be
associated with delayed diagnosis or difficulties in cultur-
ing Nocardia spp.21 To facilitate the rapid diagnosis, sev-
eral molecular techniques have been developed including
16S ribosomal DNA and hsp65 gene analysis,22 and more
recently pyrosequencing.23
In conclusion, Nocardia spp are rare causes of intracer-
ebral abscess related to the use of alefacept and infliximab
therapy. Physicians need to be aware of this diagnosis in such
patients, and prompt diagnosis and treatment are necessary
to decrease mortality and morbidity.
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